Hematopoetic stem celi transplantation activity at a single center: Cerrahpaşa experience.

At our institution 94 transplantations have been performed in an 8 year period up to December 2001. Forty-three females and 49 males with ages ranging from 14 to 61 years received 67 allogeneic (allo) and 27 autologous (auto) transplants; 2 patients were transplanted twice. The diagnosis of allo transplants were AML (27 patients-pts), CML (17 pts), ALL (16 pts) and AA (5 pts); those of auto transplants were NHL (13 pts), HD (10 pts), MM (3 pts) and AML (l pt). Of the patients with acute leukemia 69.7% were in first CR and ali but öne of the patients with CML were in first chronic phase. Source of hematopoetic stem cells were bone marrow (BM) in 61.9% (allo 81.5%, auto 14.8%) and peripheral blood (PB) in 38.1% (allo 18.5%, auto 85.2%). Ail donors were HLA-full matched siblings with öne exception. Conditionİng regimens were BU-CY (31 pts), TBI-CY (28 pts) and Flag-lda (öne pî) for leukemia, CY-ATG for AA, CBV for lymphoma and Mel-200 for MM. Median 2.69 x 108 nucieated celIsAg (BM) and 21.7 x 106 CD34 + celIsAg (PB) were infused to allo transplant recipients; 4 patients faiied to engraft and öne patient was inevaluable due to early death. Acute GVHD was observed in 11 patients (16.9% - grade ll-IV in 10.7%) and chronic GVHD was documented in 18 patients (33.9%- extensive in 9.43%). VOD was seen in 8 patients (12.3%). Early response was CR in 91.6% in patienîs wîth leukemia; patients with lymphoma showed a 73.1% response (CR & PR) rate and 23.1% had resistant disease. So far 27.6% of the patients have relapsed ör showed progression and 45.7% have died (disease-related 27.2%, transplant-related 18.5%). At a median follow-up time of 32 months (range 0.6-96) DFS is 50.8% and OS is 53.9% in the allo transplant group. With a shorter follow-up (median 16 months, range 1-65) the same figures for the auto transplant group are 51.9 and 55.5%, respectively, in this cohort overall, OS and DFS are significantly superior in patients with early-stage disease: 71.7% vs. 26.7% in advanced-stage disease for OS and 71.4% vs. 36.8% for DFS, respectively and this trend applies to both transplant groups (p< 0.001 for ali comparisons).

[1]  C. Hui,et al.  Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. , 2001, Clinical and laboratory haematology.

[2]  J. Armitage,et al.  International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Armitage,et al.  International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Deeg,et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.

[5]  N. Schmitz,et al.  Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. , 1993, British Journal of Cancer.

[6]  B. Barlogie,et al.  Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. , 1992, Blood.

[7]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[8]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[9]  D. Rosenthal,et al.  Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Rimm,et al.  Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. , 1989, Bone marrow transplantation.

[11]  R. Hoffmann,et al.  Risk factors for acute graft‐versus‐host disease , 1987, British journal of haematology.

[12]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[13]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[14]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .